Clinical trial · no report yet · Phase 3
TROPION-Lung15
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- NCT06417814 ↗
- Recruiting
- AstraZeneca
- 26 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| Podcasts | 13 | |
| YouTube | 9 | |
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Open-label, Sponsor-blind, Randomized Study of Dato-DXd With or Without Osimertinib Versus Platinum-based Doublet Chemotherapy for Participants With EGFR-mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Has Progressed on Prior Osimertinib Treatment (TROPION-Lung15)
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Metastatic Non-small Cell Lung Cancer
- Interventions
- Dato-DXd; Osimertinib; Pemetrexed; Carboplatin; Cisplatin
- Arms
- Group 1: Dato-DXd + Osimertinib Combination Therapy · Experimental
- Group 2: Dato-DXd Monotherapy · Experimental
- Group 3: Platinum-based Doublet Chemotherapy · Experimental
- Enrollment
- 744 (estimated)
- Primary outcomes
- Progression free Survival (PFS)
- Sponsor
- AstraZeneca with Daiichi Sankyo
- Start
- Oct 4, 2024
- Primary completion
- Sep 30, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT06417814 · updated May 14, 2026
Publications
linked from the registry- Tan DS, Nadal E, Cheema P, Wu YL, Ahn MJ, Tanizaki J, Grainger E, Nizialek E, Forcina A, van der Gronde T, Yu HA. TROPION-Lung15: a randomized phase III study of osimertinib combined with datopotamab deruxtecan (Dato-DXd) or Dato-DXd alone versus platinum-doublet chemotherapy in patients with EGFR-mutated advanced non-small cell lung cancer and whose disease has progressed on prior osimertinib. Ther Adv Med Oncol. 2025 Dec 23;17:17588359251385410. doi: 10.1177/17588359251385410. eCollection 2025. PubMed 41466843